Antibodies
9 September 2017
Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress8 September 2017
Seattle Genetics Highlights Promising Data with Tisotumab Vedotin in Cervical Cancer at ESMO 2017 Congress8 September 2017
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration8 September 2017
Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer7 September 2017
TRACON Pharmaceuticals Announces Completion of Enrollment in Randomized Phase 2b TRAXAR Study of TRC105 and Inlyta® in Renal Cell Carcinoma7 September 2017
InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa7 September 2017
Bristol-Myers Squibb Provides an Update on Three Opdivo-based Combination Clinical Studies in Multiple Myeloma7 September 2017
Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma6 September 2017
Valerion Presents Preclinical Proof-of-Concept Data for VAL-0417 for the Treatment of Lafora Disease6 September 2017
MacroGenics Advances Two First-in-Class Clinical DART® Molecules5 September 2017
TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial2 September 2017
Five Prime Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress1 September 2017
MacroGenics Announces Termination of Duvortuxizumab Collaboration and License Agreement with Janssen1 September 2017
Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/ES41430 August 2017
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release SyndromeNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports